Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: A review of epidemiological and experimental data

Gynecological Endocrinology

Volumn 19, Issue 4, 2004, Pages 216-228

  Gadducci, A ^a   Cosio, S ^a   Gargini, A ^a   Genazzani, A R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Gonadotropin; Ovarian Carcinogenesis; Sex steroid Hormones

Indexed keywords

CETRORELIX; ESTRADIOL; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; HORMONE RECEPTOR; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; SEX HORMONE; STEROID HORMONE; TAMOXIFEN; TRIPTORELIN;

CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; FAMILIAL CANCER; FERTILITY; GENE MUTATION; GYNECOLOGY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MENSTRUAL CYCLE; MORTALITY; ONCOGENE; ONCOLOGY; ORAL CONTRACEPTION; OVARY CARCINOMA; OVARY TUMOR; PARITY; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SURVIVAL TIME;

CELL DIVISION; CONTRACEPTIVES, ORAL; EPITHELIAL CELLS; FEMALE; GONADAL STEROID HORMONES; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HORMONE ANTAGONISTS; HUMANS; OVARIAN NEOPLASMS; PREGNANCY; PROGESTINS; RECEPTORS, GONADOTROPIN; RECEPTORS, STEROID;

EID: 12244271083     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590400014354     Document Type: Review

References (132)

1. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev 2001;10: 125-9
2. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10
3. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001;6:107-38
4. Tingulstad S, Skjeldestad FE, Halvorsen TB, et al. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003;101:885-91
5. O'Malley CD, Cress RD, Campleman SL, et al. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol 2003;91:608-15
6. Baker TR, Piver MS, Hempling RE. Long-term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 1994; 74:656-63
7. Li AJ, Karlan BY. Surgical advances in the treatment of ovarian cancer. Hematol Oncol Clin North Am 2003;17:945-56
8. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6
9. du Bois A, Luck HJ, Meier W, et al. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. Semin Oncol 1997;24 (Suppl 15):15-52
10. Conte PF, Cianci C, Gadducci A. Up date in the management of advanced ovarian carcinoma. Crit Rev Oncol Hematol 1999;32:49-58
11. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708
12. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18:3084-92
13. Ozols RF, Bundy BN, Greer BE, et al., Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200
14. Stratton JF, Pharoah P, Smith SK, et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998;105:493-9
15. Greggi S. BRCA1-BRCA2 and ovarian cancer. In Genazzani AR, ed. Hormone Replacement Therapy and Cancer. The current status of research and practice. New York: Parthenon Publishing, 2002:207-17
16. Volm T. Familial ovarian cancer. Curr Wom Health Rep 2002;2:34-8
17. Swisher E. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2. Curr Wom Health Rep 2003;3:27-32
18. Reedy M, Gallion H, Fowler JM, et al. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2002;85:255-9
19. Narod SA, Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 2002;14:19-26
20. Gertig DM, Hunter DJ, Cramer DW et al. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst 2000;92:249-52
21. Huncharek M, Geschwind JF, Kupelnick B. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies. Anticancer Res 2003;23:1955-60
22. Bosetti C, Negri E, Franceschi S, et al. Diet and ovarian cancer risk: a case-control study in Italy. Int J Cancer 2001;93:911-15
23. McCann SE, Moysich KB, Mettlin C. Intakes of selected nutrients and food groups and risk of ovarian cancer. Nutr Cancer 2001;39:19-28
24. Zhang M, Lee AH, Binns CW. Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecol Oncol 2004;92:320-6
25. Wehner AP. Cosmetic talc should not be listed as a carcinogen: comments on NTP's deliberations to list talc as a carcinogen. Regul Toxicol Pharmacol 2002;36:40-50
26. Modugno F, Ness RB, Allen GO, Alcohol consumption and the risk of mucinous and nonmucinous epithelial ovarian cancer. Obstet Gynecol 2003;102:1336-43
27. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003;158:629-38
28. Tavani A, Ricci E, La Vecchia C, et al. Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. Int J Epidemiol 2000;29:799-802
29. Negri E, Franceschi S, Tzonou A, et al. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991;49:50-6
30. Franceschi S, La Vecchia C, Booth M, et al. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 1991;49:57-60
31. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344:1250-4
32. Albrektsen G, Heuch I, Kvale G. Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study. Cancer Causes Control 1996;7:421-7
33. Cramer DW, Hutchison B, Welch WR, et al. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-16
34. Bandera CA., Cramer DW, Freiedman AJ, et al. Fertility therapy in the setting of a history of invasive epithelial ovarian cancer. Gynecol Oncol 1995;58:116-9
35. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86
36. Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology 1999;57 (Suppl 2):45-8
37. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;36:1184-203
38. Anderson SM, Dimitrievich E. Ovulation induction for infertility: is it safe or not? S D J Med 1996;49:419-21
39. Parazzini F, Pelucchi C, Negri E, et al. Use of fertility drugs and risk of ovarian cancer. Hum Reprod 2001;16:1372-5
40. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-24
41. Ghahremani M, Foghi A, Dorrington JH. Etiology of ovarian cancer: a proposed mechanism. Med Hypotheses 1999;52:23-6
42. Purdie DM, Bain CJ, Siskind V, et al. Ovulation and risk of epithelial ovarian cancer. Int J Cancer 2003;104:228-32
43. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002;156:363-73
44. Siskind V, Green A, Bain C et al. Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 2000;11:106-10
45. Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002;102:262-5
46. Burkman RT. Reproductive hormones and cancer: ovarian and colon cancer. Obstet Gynecol Clin North Am 2002;29:527-40
47. Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. Ann NY Acad Sci 2003;997:199-208
48. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 2000;52:233-41
49. Sanderson M, Williams MA, Weiss NS, et al. Oral contraceptives and epithelial ovarian cancer. Does dose matter? J Reprod Med 2000;45:720-6
50. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001;95:370-4
51. Schildkraut JM, Calingaert B, Marchbanks PA, et al. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-8
52. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-8
53. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-9
54. Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replace-ment therapy. Br J Obstet Gynaecol 1987;94:620-35
55. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989;60:592-8
56. Persson I, Yuen J, Bergkvist L, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32
57. Hempling RE, Wong C, Piver MS, et al. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 1997;89:1012-6
58. Gadducci A, Fanucchi A, Cosio S, et al. Hormone replacement therapy and gynecological cancer. Anticancer Res 1997;17:3793-8
59. Garg PP, Kerlikowske K, Subak L, et al. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998;92:472-9
60. Purdie DM, Bain CJ, Siskind V, et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 1999;81:559-63
61. Coughlin SS, Giustozzi A, Smith SJ, et al. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53: 367-75
62. La Vecchia C, Brinton LA, McTiernan A. Menopause, hormone replacement therapy and cancer. Maturitas 2001;39:97-115
63. Genazzani AR, Gadducci A, Gambacciani M, International Menopause Society Expert Workshop. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. Maturitas 2001;40:117-30
64. Sit AS, Modugno F, Weissfeld JL, et al. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 2002;86:118-23
65. Rodriguez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J Am Med Assoc 2001;21:1460-5
66. Lacey JV Jr, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. J Am Med Assoc 2002;288:334-41
67. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504
68. American Medical Association. Long-term use of estrogen-only hormone replacement therapy (HRT) linked with increased risk of ovarian cancer. Ginecol Obstet Mex 2002;70:409-10
69. Anderson GL, Judd HL, Kaunitz AM, et al., Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecolocic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. J Am Med Assoc 2003;290:1739-48
70. Eeles RA, Tan S, Wiltshaw E, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. Br Med J 1991;302:259-62
71. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999;86:1013-18
72. Burger CW, van Leeuwen FE, Scheele F, et al. Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 1999;32: 69-76
73. Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 2001;8:70-5
74. Parrott JA, Doraiswamy V, Kim G, et al. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 2001;172:213-22
75. Zheng W, Lu JJ, Luo F, et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000;76:80-8
76. Emons G, Ortmann O, Becker M, et al. High affinity binding and direct antipfoliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993;53:5439-46
77. Miyazaki M, Nagy A, Schally AV, et al. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 1997;89:1803-9
78. Volker P, Grundker C, Schmidt O, et al. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 2002;186:171-9
79. Kang SK, Choi KC, Yang HS, et al. Potential role of gonadotropin- releasing hormone (GnRH)-1 and GnRH-2 in the ovary and ovarian cancer. Endocr Relat Cancer 2003;10:169-77
80. Fujimoto J, Hirose R, Sakaguchi H, et al. Clinical significance of expression of estrogen receptor alpha and beta mRNAs in ovarian cancers. Oncology 2000;58:334-41
81. Sakaguchi H, Fujimoto J, Aoki I, et al. Expression of oestrogen receptor α and β in uterine endometrial and ovarian cancers. Eur J Cancer 2002;38 (Suppl 6):S74-5
82. Taube M, Hockenstrom T, Isaksson M, et al. Effects of sex steroids on survival and receptor expression in ovarian epithelial tumour cells. Int J Oncol 2003;22:1257-62
83. Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol 2003;189:22-7
84. Del Carmen MG, Smith Sehdev AE, Fader AN, et al. Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer 2003;98:1658-63
85. Lindgren P, Backstrom T, Mahlck CG, et al. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Int J Oncol 2001;19:31-8
86. Fujimura M, Hidaka T, Kataoka K, et al. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid and mucinous adenocarcinoma. Am J Surg Pathol 2001;25:667-72
87. Akahira J, Inoue T, Suzuki T, et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer 2000;83:1488-94
88. Cardillo MR, Petrangeli E, Aliotta N, et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 1998;17:231-7
89. Li AJ, Baldwin RL, Karlan BY. Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res 2003;9:3667-73
90. Modugno F. Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: A HuGE review. Am J Epidemiol 2004;159:319-35
91. Choi KC, Kang SK, Tai CJ, et al. Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2002;87:2245-53
92. Syed V, Ulinski G, Mok SC, et al. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-76
93. Stewart SL, Querec TD, Gruver BN, et al. Gonadotropin and steroid hormones stimulate proliferation of the rat ovarian surface epithelium. J Cell Physiol 2004;198:119-24
94. Peterson CM, Jolies CJ, Carrell DT, et al. GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol Oncol 1994;52:26-30
95. Kang SK, Cheng KW, Nathwani PS, et al. Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. Endocrine 2000;13:297-304
96. Furui T, Imai A, Tamaya T. Intratumoral level of gonadotropin-releasing hormone in ovarian and endometrial cancers. Oncol Rep 2002;9:349-52
97. Thompson MA, Adelson MD, Kaufman LM. Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 1991;72:1036-41
98. Sridaran R, Hisheh S, Dharmarajan AM. Induction of apoptosis by a gonadotropin-releasing hormone agonist during early pregnancy in the rat. Apoptosis 1998;3:51-7
99. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56
100. Grundker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 2003;1:65
101. Emons G, Muller B, Ortmann O, et al. Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal trasduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. Int J Oncol 1996;9:1129-37
102. Ohta H, Sakamoto H, Satoh K. In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum. Cancer Lett 1998;134:111-8
103. Yano T, Pinski J, Radulovic S, et al. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1994;91:1701-5
104. Tang X, Yano T, Osuga Y, et al. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. J Clin Endocrinol Metab 2002;87:3721-7
105. Choi KC, Kang SK, Tai CJ, et al. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 2001;142:23 51-60
106. Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Invest 1998;5:271-6
107. Rodriguez GC, Nagarsheth NP, Lee KL, et al. Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 2002;94:50-60
108. Syed V, Ho SM. Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 2003;22:6883-90
109. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86
110. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. J Am Med Assoc 1995;274:1926-30
111. Silva EG, Tornos C, Pritsche HA, et al. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 1997;10:879-83
112. Evangelou A, Jindal SK, Brown TJ, et al. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 2000;60:929-35
113. Slotman BJ, Rao BR. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res 1988;8:417-34
114. van der Vange N, Greggi S, Burger CW, et al. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 1995;34:813-20
115. Gadducci A, Genazzani AR. Endocrine therapy for gynecological cancer. Gynecol Endocrinol 1999;13:441-56
116. Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2001; CD001034
117. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future reseach. Gynecol Oncol 2002;84:201-9
118. Langdon SP, Gabra H, Bartlett JM, et al. Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. Clin Cancer Res 1998;4:2245-51
119. Hamerlynck JV, Maskens AP, Mangioni C, et al. Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study. Gynecol Oncol 1985;22:313-16
120. Bowman A, Gabra H, Langdon SP, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002;8:2233-9
121. Emons G, Schulz KD. Primary and salvage therapy with LH-RH analogues in ovarian cancer. Rec Results Cancer Res 2000;153:83-94
122. Zidan J, Zohar S, Mijiritzky I, et al. Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy. Isr Med Assoc J 2002;4:597-9
123. Duffaud F, van der Burg ME, Namer M, et al. TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study. Anticancer Drugs 2001;12:159-62
124. du BA, Meier W, Luck HJ, et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 2002;13:251-7
125. Emons G, Ortmann O, Teichert HM, et al. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 1996;78:1452-60
126. Verschraegen CF, Westphalen S, Hu W, et al. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol 2003;90:552-9
127. Tumolo S, Rao BR, van der Burg ME, et al. Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study. Eur Cancer 1994;30A:911-4
128. Vassilomanolakis M, Koumakis G, Barbounis V, et al. A phase II study of flutamide in ovarian cancer. Oncology 1997;54:199-202
129. Rocereto TF, Saul HM, Aikins JA Jr, et al. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol 2000;77:429-32
130. Rodriguez G. New insights regarding pharmacologic approaches for ovarian cancer prevention. Hematol Oncol Clin North Am 2003;17:1007-20
131. See HT, Kavanagh JJ, Hu W, et al. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 2003;13:701-34
132. du Bois A, Pfisterer J, Meier W, et al. Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective. Int J Gynecol Cancer 2003;13 (Suppl 2):169-71